Newsroom
Product launches, research breakthroughs, and company milestones from the Vecentra team.
The most valuable signal in early cancer drug design is not raw potency, it is selectivity. A note on why predicting cytotoxicity well means predicting biology, and how multi-omics nudges models toward mechanism instead of memorisation.
Read storyAn early company note on who is building Gnosis, what the resources are for, and why we are not going to pretend a round announcement is the interesting part.
Read storyThe product is not an endpoint. It is a decision about which molecules to make next, delivered as a Candidate Intelligence Codex rather than an unattended API.
Read storyGenerators can fill a drive with plausible structures before the coffee cools. The scarce thing is a molecule that is still interesting after selectivity, exposure, and toxicity have voted.
Read storyStarting in cancer is where selectivity, safety, and pathway response can be learned together. Neurodegeneration is how we find out whether those lessons survive a different organ.
Read story